Observational studyBMC cancer2026

Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.

Zhengjun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.